International
The Morning Science

What science found today

‹
 

Research

Cell-free RNA signatures derived from the tumor microenvironment predict outcomes of CAR T therapy in large B cell lymphoma

Cell Reports Medicine · By Conor Loy, Glory Agun, Katie Maurer, Anna Bosch-Vilaseca, Daria Potapova, Caron A. Jacobson, Jerome Ritz & Iwijn De Vlaminck ·

The Brief

  • Plasma cell-free RNA collected before anti-CD19 CAR T cell infusion predicts long-term treatment response in large B cell lymphoma, according to Loy et al.
  • The study uses tumor microenvironment-derived archetypes and unbiased feature discovery to identify these RNA signatures.
  • The authors report that plasma cell-free RNA captures signals from the tumor microenvironment.

Why it matters

A blood-based RNA signature measured before infusion could help clinicians anticipate which lymphoma patients are likely to respond durably to CAR T therapy, without needing tumor biopsies.

Who’s affected

  • clinical oncologists and hematologists treating large B cell lymphoma
  • researchers working on CAR T cell therapy and liquid biopsy biomarkers

Loy et al. show that plasma cell-free RNA collected before anti-CD19 CAR T cell infusion predicts long-term treatment response. Using tumor microenvironment-derived archetypes and unbiased feature discovery, they find that plasma cell-free RNA captures signals from the tumor…

Timeline

  1. Study published in Cell Reports Medicine

  2. cell.com

    Cell-free RNA signatures derived from the tumor microenvironment predict outcomes of CAR T therapy in large B cell lymphoma

How do you feel about this?

0 Comments

    Cell-free RNA signatures derived from the tumor microenvironment predict outcomes of CAR T therapy in large B cell lymphoma – The Morning Science